Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05551117 · OUTCOME

Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors · Source last updated 2026-02-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.

What was measured

The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.

Analysis population: All participants who received at least one dose of study treatment and had RECIST-evaluable disease per RECIST v1.1 (Tumor Response Evaluable Population) in Part 2 of the study.

Groups in this outcome

Part 2

vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 24

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    units
    Participants
description
The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.
groups
  1. description
    vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks
    id
    OG000
    title
    Part 2
param Type
NUMBER
population Description
All participants who received at least one dose of study treatment and had RECIST-evaluable disease per RECIST v1.1 (Tumor Response Evaluable Population) in Part 2 of the study.
reporting Status
POSTED
time Frame
Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
title
Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice